International Assets Investment Management LLC Buys Shares of 53,508 Arvinas, Inc. (NASDAQ:ARVN)

International Assets Investment Management LLC purchased a new stake in shares of Arvinas, Inc. (NASDAQ:ARVN - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 53,508 shares of the company's stock, valued at approximately $2,202,000. International Assets Investment Management LLC owned about 0.10% of Arvinas as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently bought and sold shares of the stock. Corton Capital Inc. increased its holdings in shares of Arvinas by 132.9% during the 3rd quarter. Corton Capital Inc. now owns 21,750 shares of the company's stock worth $427,000 after acquiring an additional 12,411 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its stake in Arvinas by 363.6% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,370 shares of the company's stock valued at $262,000 after acquiring an additional 4,996 shares during the last quarter. Capula Management Ltd acquired a new position in shares of Arvinas during the 3rd quarter worth $808,000. Vanguard Group Inc. lifted its holdings in shares of Arvinas by 2.0% in the third quarter. Vanguard Group Inc. now owns 4,608,223 shares of the company's stock worth $90,505,000 after acquiring an additional 90,426 shares during the last quarter. Finally, FMR LLC boosted its position in Arvinas by 10.6% in the third quarter. FMR LLC now owns 4,868,295 shares of the company's stock valued at $95,613,000 after buying an additional 466,667 shares in the last quarter. 95.19% of the stock is currently owned by institutional investors.

Insider Activity at Arvinas

In other Arvinas news, insider Ronald Peck sold 1,699 shares of the firm's stock in a transaction dated Friday, February 23rd. The stock was sold at an average price of $47.05, for a total value of $79,937.95. Following the completion of the transaction, the insider now owns 67,516 shares in the company, valued at approximately $3,176,627.80. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In related news, insider Ronald Peck sold 1,699 shares of Arvinas stock in a transaction on Friday, February 23rd. The stock was sold at an average price of $47.05, for a total transaction of $79,937.95. Following the completion of the sale, the insider now owns 67,516 shares of the company's stock, valued at $3,176,627.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Sean A. Cassidy sold 1,702 shares of the business's stock in a transaction dated Friday, February 23rd. The stock was sold at an average price of $47.05, for a total value of $80,079.10. Following the transaction, the chief financial officer now owns 181,916 shares of the company's stock, valued at $8,559,147.80. The disclosure for this sale can be found here. In the last ninety days, insiders sold 8,597 shares of company stock worth $404,489. Corporate insiders own 5.23% of the company's stock.

Arvinas Stock Up 0.4 %

ARVN traded up $0.13 during midday trading on Monday, reaching $31.57. The company had a trading volume of 503,061 shares, compared to its average volume of 715,834. The business has a 50-day moving average price of $38.40 and a two-hundred day moving average price of $35.94. Arvinas, Inc. has a 12-month low of $13.57 and a 12-month high of $53.08.

Arvinas (NASDAQ:ARVN - Get Free Report) last released its earnings results on Tuesday, May 7th. The company reported ($0.97) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.42) by $0.45. The business had revenue of $25.30 million during the quarter, compared to the consensus estimate of $32.94 million. Arvinas had a negative return on equity of 64.79% and a negative net margin of 185.09%. The business's revenue for the quarter was down 22.2% on a year-over-year basis. During the same period last year, the business posted ($1.54) earnings per share. As a group, equities analysts expect that Arvinas, Inc. will post -4.23 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages recently issued reports on ARVN. HC Wainwright reiterated a "buy" rating and set a $87.00 target price on shares of Arvinas in a research report on Wednesday, May 8th. Truist Financial reissued a "buy" rating and issued a $65.00 price objective on shares of Arvinas in a research note on Monday, March 25th. Barclays lifted their target price on Arvinas from $26.00 to $60.00 and gave the stock an "overweight" rating in a report on Thursday, February 29th. Citigroup cut Arvinas from a "buy" rating to a "neutral" rating and increased their price target for the company from $36.00 to $55.00 in a research note on Wednesday, February 14th. Finally, Oppenheimer reaffirmed an "outperform" rating and issued a $80.00 price objective (down from $95.00) on shares of Arvinas in a research note on Wednesday, February 28th. Two equities research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $61.13.

About Arvinas

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.